



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/216164/>

Version: Supplemental Material

Article:

Mukherjee, S., Qi, C., Shaw, R. et al. (2024) Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. *European Journal of Cancer*, 209. 114236. ISSN: 0959-8049

<https://doi.org/10.1016/j.ejca.2024.114236>


© 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. This is an author produced version of an article published in *European Journal of Cancer* made available under the CC-BY-NC-ND 4.0 license (<http://creativecommons.org/licenses/by-nc-nd/4.0>) in accordance with the publisher's self-archiving policy.

Reuse


Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown


If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.




Supplementary Figure 1: CONSORT flow diagram of stage 1 of the SCALOP-2 trial.




Supplementary figure 2: Kaplan Meier estimates for stage 2 patients receiving chemoradiotherapy of overall survival by radiation dose in (A) patients randomized to nelfinavir and (B) patients who were not randomized to nelfinavir.




Supplementary figure 3: Kaplan Meier estimates for stage 2 patients receiving chemoradiotherapy of progression free survival by nelfinavir usage in (A) patients randomized to standard dose radiation and (B) patients randomized to high dose radiation.




Supplementary figure 4: Global Health Status score by stage 2 treatment arm (standard versus high dose chemoradiotherapy)



Supplementary figure 5: Global Health Status score by stage 2 treatment arm (with or without nelfinavir)



Supplementary figure 6: EQ-5D-5L score by stage 2 treatment arm (standard versus high dose chemoradiotherapy)



Supplementary figure 7: EQ-5D-5L score by stage 2 treatment arm (with or without nelfinavir)